Braxia Scientific Corp.

Equities

BRAX

CA1057361026

Healthcare Facilities & Services

Market Closed - Canadian Securities Exchange Other stock markets 14:32:21 2024-05-31 EDT			5-day change	1st Jan Change
0.005 ^CAD	-.--%		-.--%	-50.00%

02-29	Braxia Scientific Corp. Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2023	CI
2023	Braxia Scientific Corp. Announces Board Changes	CI

Braxia Scientific signs non-binding letter of intent to sell company to Irwin Naturals

February 07, 2023 at 12:03 pm

(via NewsDirect)

Braxia Scientific CEO Dr Roger McIntyre joined Steve Darling from Proactive to share news the company has agreed to a non-binding amended and restated letter of intent for a business combination with Irwin Naturals Inc.

McIntyre told Proactive the transaction assembles an experienced management and scientific team in mental health treatment, research and development. The combined company will have 17 specialized mental health clinics across North America, an enhanced telehealth platform and access to critical treatments for millions of people across multiple states in the US.

Contact Details

Proactive Canada

+1 604-688-8158

na-editorial@proactiveinvestors.com

Latest news about Braxia Scientific Corp.

Braxia Scientific Corp. Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2023	02-29	CI
Braxia Scientific Corp. Announces Board Changes	11-30	CI
Braxia Scientific Corp. Announces CFO Changes	11-30	CI
Braxia Scientific Corp. Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2023	11-28	CI
Braxia Scientific Corp. Reports Earnings Results for the First Quarter Ended June 30, 2023	23-08-28	CI
Braxia Scientific Corp. Reports Earnings Results for the Full Year Ended March 31, 2023	23-07-30	CI
Braxia Scientific Provides Operations Update	23-06-09	MT
Irwin Naturals Launches New Product in Canada	23-03-24	MT
Irwin Naturals Brief: Says Cannabis Products Launch Nationwide in Canada	23-03-24	MT
Irwin Naturals Closes Purchase of Ketamine Media	23-03-22	MT
Irwin Naturals Brief: CEO of Irwin Naturals, Klee Irwin, Expressed Disappointment on the Announcement, But Recognized the Decision was "Based on a Lack of a Clear Business Rationale for the Company to move forward with the Transaction"	23-03-16	MT
Irwin Naturals Brief: Says has terminated Non-binding amended and restated letter of intent for a business combination with Braxia Scientific Corp.	23-03-16	MT
Irwin Naturals Inc. cancelled the acquisition of Braxia Scientific Corp..	23-03-15	CI
Braxia Scientific Corp. Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2022	23-02-28	CI
Braxia Scientific Corp. announced that it has received CAD 0.513 million in funding	23-02-26	CI
Irwin Naturals Closes Purchase of Kentucky Clinic	23-02-21	MT
Braxia Scientific Corp. announced that it expects to receive CAD 1.5 million in funding	23-02-06	CI
Refile: Irwin Naturals Secures Credit Facility For Up To US$60 Million	23-02-02	MT
Irwin Naturals Brief: Says Secured US$40 Million of Financing for its Current Operations including Psychedelic Mental Health Clinic Rollup, Potential for up to $60 Million	23-02-02	MT
Irwin Naturals Brief: Says Signed Letter of Intent to Acquire Braxia Scientific	23-01-30	MT
Irwin Naturals Reports Letter of Intent to Purchase Braxia Scientific	23-01-27	MT
Irwin Naturals Brief: And a deemed value per subordinate voting share and/or proportionate voting share of Irwin equal to the greater of US$3.00 and the volume weighted average trading price of Irwin Shares on the CSE	23-01-27	MT
Irwin Naturals Brief: Under the terms of the LOI, Irwin Prepared to Offer a purchase price per Braxia Share based upon a valuation of the outstanding Braxia Shares of US$30 Million	23-01-27	MT
Irwin Naturals Brief: Signing Letter of Intent to Acquire Braxia Scientific	23-01-27	MT
Irwin Naturals Inc. signed letter of intent to acquire Braxia Scientific Corp. for CAD 39.9 million.	23-01-26	CI

Chart Braxia Scientific Corp.

Duration

Period

More charts

Company Profile

Braxia Scientific Corp. is a Canada-based company, which is primarily focused on owning and operating multidisciplinary clinics, providing treatment for mental health disorders, and research activities related to discovering and commercializing drugs and delivery methods. The Company seeks to develop ketamine and derivatives and other psychedelic products from its Internet protocol (IP) development platform. The Company has clinic operations in the Canadian cities of Mississauga, Toronto, Kitchener-Waterloo, Ottawa and Montreal. The Company, through its wholly owned subsidiary, the Canadian Rapid Treatment Center of Excellence Inc., it operates multidisciplinary community-based clinics offering rapid-acting treatments for depression located in Mississauga, Toronto, Ottawa, Kitchener and Montreal. Its subsidiaries include Altmed Capital Corp., Artisan Growers Ltd., KetaMD, Inc., Novo Formulations Ltd. and Tassili Life Sciences Corp.

Sector

Healthcare Facilities & Services

Calendar

2024-07-28 - Q4 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Sector Other Healthcare Facilities & Services

	1st Jan change	Capi.
BRAXIA SCIENTIFIC CORP.	-50.00%	1.04M
HCA HEALTHCARE, INC.	+25.52%	88.99B
CVS HEALTH CORPORATION	-24.52%	74.82B
DR. SULAIMAN AL HABIB MEDICAL SERVICES GROUP COMPANY	-5.56%	25.03B
FRESENIUS SE & CO. KGAA	+4.31%	17.88B
LABCORP HOLDINGS INC.	-14.25%	16.43B
QUEST DIAGNOSTICS INCORPORATED	+2.97%	15.77B
NATERA, INC.	+70.11%	13.09B
TENET HEALTHCARE CORPORATION	+79.20%	13.21B
DAVITA INC.	+40.44%	12.9B

Other Healthcare Facilities & Services